437 related articles for article (PubMed ID: 11181372)
21. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.
Berenguer J; Ali NM; Allende MC; Lee J; Garrett K; Battaglia S; Piscitelli SC; Rinaldi MG; Pizzo PA; Walsh TJ
Antimicrob Agents Chemother; 1994 Jun; 38(6):1303-8. PubMed ID: 8092829
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats.
Ullmann AJ; Krammes E; Sommer S; Buschmann I; Jahn-Muehl B; Cacciapuoti A; Schmitt HJ
J Antimicrob Chemother; 2007 Nov; 60(5):1080-4. PubMed ID: 17855727
[TBL] [Abstract][Full Text] [Related]
23. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
24. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis.
Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II
Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus.
Gonzalez CE; Lyman CA; Lee S; Del Guercio C; Roilides E; Bacher J; Gehrt A; Feuerstein E; Tsokos M; Walsh TJ
Cytokine; 2001 Jul; 15(2):87-95. PubMed ID: 11500084
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamics of the Orotomides against
Hope WW; McEntee L; Livermore J; Whalley S; Johnson A; Farrington N; Kolamunnage-Dona R; Schwartz J; Kennedy A; Law D; Birch M; Rex JH
mBio; 2017 Aug; 8(4):. PubMed ID: 28830945
[TBL] [Abstract][Full Text] [Related]
27. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.
Alvarez CA; Wiederhold NP; McConville JT; Peters JI; Najvar LK; Graybill JR; Coalson JJ; Talbert RL; Burgess DS; Bocanegra R; Johnston KP; Williams RO
J Infect; 2007 Jul; 55(1):68-74. PubMed ID: 17360039
[TBL] [Abstract][Full Text] [Related]
28. Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis.
Gebremariam T; Alkhazraji S; Gu Y; Singh S; Alqarihi A; Shaw KJ; Ibrahim AS
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685475
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.
Gastine S; Hope W; Hempel G; Petraitiene R; Petraitis V; Mickiene D; Bacher J; Walsh TJ; Groll AH
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168606
[No Abstract] [Full Text] [Related]
30. Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis.
Petraitis V; Petraitiene R; Lin P; Calis K; Kelaher AM; Muray HA; Mya-San C; Mickiene D; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2005 Apr; 49(4):1642-5. PubMed ID: 15793161
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of intravenous itraconazole against invasive pulmonary aspergillosis in neutropenic mice.
Tansho S; Abe S; Ishibashi H; Torii S; Otani H; Ono Y; Yamaguchi H
J Infect Chemother; 2006 Dec; 12(6):355-62. PubMed ID: 17235640
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.
Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A
Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554
[TBL] [Abstract][Full Text] [Related]
33. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6767-72. PubMed ID: 25182639
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
Chandrasekar PH; Cutright JL; Manavathu EK
Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.
Petraitis V; Petraitiene R; Sarafandi AA; Kelaher AM; Lyman CA; Casler HE; Sein T; Groll AH; Bacher J; Avila NA; Walsh TJ
J Infect Dis; 2003 Jun; 187(12):1834-43. PubMed ID: 12792859
[TBL] [Abstract][Full Text] [Related]
37. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
38. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.
Patterson TF; George D; Ingersoll R; Miniter P; Andriole VT
Antimicrob Agents Chemother; 1991 Oct; 35(10):1985-8. PubMed ID: 1759818
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.
Petraitiene R; Petraitis V; Kelaher AM; Sarafandi AA; Mickiene D; Groll AH; Sein T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2005 May; 49(5):2084-92. PubMed ID: 15855534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
